In a groundbreaking study poised to reshape the landscape of cancer treatment, researchers from the National University of Singapore (NUS) have unveiled a novel molecular target that could significantly enhance the efficacy of cancer immunotherapies. This target, protein tyrosine phosphatase 1B (PTP1B), acts as a crucial regulatory switch in the induction of immunogenic cell death (ICD), a specialized form of cell death capable of stimulating the body’s adaptive immune response. The findings, detailed in a recent publication in the Journal of the American Chemical Society, mark a major breakthrough in understanding how ICD can be pharmacologically triggered in cancer cells, opening new avenues for chemotherapy that not only kills tumors directly but also promotes durable immune protection against cancer relapse.
Immunogenic cell death distinguishes itself from other forms of regulated cell death by its ability to activate the immune system against the dying cells. This modality of cell death does not merely eliminate malignant cells; it educates the immune system to recognize and combat residual or future cancerous threats. The dual therapeutic advantage of ICD has driven intense research efforts aimed at identifying drugs and molecular targets capable of triggering this immune-stimulating effect. However, until now, the specific protein targets that mediate the ICD pathway have remained elusive, masking the true mechanistic underpinnings critical for tailored drug development.
The research team at NUS, led by Professor ANG Wee Han from the Department of Chemistry, has synthesized two novel platinum-based compounds—Pt-NHC and PlatinER (Pt-ER)—that have demonstrated potent ICD-inducing properties. These organoplatinum complexes were tested in preclinical models of colorectal cancer with impressive outcomes. Treatment with these compounds not only resulted in effective tumor cell death but also conferred long-term protective immunity against tumor rechallenge, a hallmark indicator of successful ICD. The collaborative work also involved Associate Professor Maria Babak from City University of Hong Kong, whose expertise complemented the cellular immunology analyses.
Unraveling the molecular target of Pt-ER required innovative methodological approaches. The team engineered photoactivatable derivatives of Pt-ER that could covalently bind to their intracellular targets upon exposure to light, acting as bespoke molecular beacons. These “tagged” proteins were then isolated using bioconjugation techniques involving click chemistry, followed by enrichment protocols. Advanced tandem mass tag (TMT) quantitative proteomic analysis allowed the researchers to comprehensively profile the Pt-ER interactome within cancer cells. Statistical prioritization pinpointed PTP1B as a direct and functionally relevant target attached by these compounds.
Further biochemical assays confirmed that both Pt-ER and Pt-NHC directly bind to and inhibit PTP1B enzymatic activity. PTP1B is a protein tyrosine phosphatase known to modulate several signaling cascades involved in cell proliferation and immune regulation. Its inhibition precipitated the activation of immunogenic pathways leading to ICD. Strikingly, genetic knockout or pharmacological blockade of PTP1B mirrored the effects of the platinum compounds, yielding enhanced ICD and immune activation within malignant cells. These observations were corroborated by bioinformatics analyses of public colorectal cancer datasets, highlighting correlations between PTP1B expression, tumor progression, and immune evasion.
This monumental discovery positions PTP1B as a pivotal immune checkpoint within cancer cells that can be exploited to reroute cellular death toward immunogenic outcomes. The implication for cancer chemoimmunotherapy is profound. By pharmacologically targeting PTP1B, it may be possible to convert non-immunogenic forms of cell death into immunostimulatory events, effectively turning tumors into vaccines against themselves. This mechanistic insight bridges the gap between molecular pharmacology and immune oncology, providing a tangible target for next-generation anticancer agents capable of orchestrating robust anti-tumor immunity.
Professor Ang eloquently summarized the significance of this research, stating, “Our findings reveal that PTP1B is intricately linked to the immune-stimulating effects of our platinum-based ICD inducers. Understanding the molecular dialogue between these compounds and PTP1B is the next crucial phase.” The team intends to pursue detailed structural biology and molecular dynamics simulations to elucidate the exact binding modes and conformational changes induced in PTP1B by PlatinER. Such knowledge could guide the rational design of even more effective ICD inducers.
The research innovations do not only hold promise for colorectal cancer but could revolutionize treatment paradigms across a spectrum of malignancies where immune evasion is a key driver of therapeutic resistance. As immunotherapy gains prominence alongside traditional chemotherapy and radiation, strategic targeting of molecules like PTP1B could enhance patient responses and reduce relapse rates by ensuring the immune system remains vigilant against residual disease.
Beyond their therapeutic potential, the platinum compounds Pt-ER and Pt-NHC also serve as valuable chemical biology tools to dissect the complex interplay between phosphatase signaling and immune activation within the tumor microenvironment. This dual role accelerates the pace of discovery, facilitating both mechanistic insights and drug development in tandem.
The success of this study owes much to the interdisciplinary collaboration that marries synthetic chemistry, proteomics, molecular biology, and immunology. Such holistic investigations underscore the power of combining cutting-edge technologies and expertise to tackle one of oncology’s greatest challenges: harnessing the immune system to eradicate cancer effectively.
Looking ahead, the NUS team envisions expanding their research to investigate the pharmacokinetics, toxicity profiles, and in vivo efficacy of their ICD-inducing platinum complexes in more complex animal models. Concurrently, efforts to identify and validate other potential regulators within this newly characterized ICD pathway may yield additional drug targets, amplifying the therapeutic arsenal against cancer.
This pivotal advancement in cancer research highlights the intricate balance between cell death and immune activation, and the innovative chemical strategies that can tip this balance in favor of durable, immune-mediated tumor clearance. The identification of PTP1B as an essential switch for inducing immunogenic cell death opens a new chapter in cancer chemoimmunotherapy, with the potential to transform clinical outcomes for millions of patients worldwide.
Subject of Research: Animals
Article Title: Organoplatinum(II) Type II Immunogenic Cell Death Inducers Target Protein Tyrosine Phosphatase 1B to Drive Immunogenicity
News Publication Date: 21-Jan-2026
Web References: http://dx.doi.org/10.1021/jacs.5c18904
Image Credits: National University of Singapore
Keywords
Cancer immunotherapy, Immunogenicity, Medicinal chemistry
Tags: adaptive immune response activationcancer immunotherapy targetschemotherapy and immune protectionenhancing immunogenicity in cancerimmune system education in oncologyimmunogenic cell death mechanismsmolecular targets in cancer treatmentNUS cancer research breakthroughspharmacological induction of ICDprotein tyrosine phosphatase 1B roletargeted cancer immunotherapy developmenttumor relapse prevention strategies
